Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.64 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772974 | 1.00 | CTSK (0.64) | CTSKGRIA1HDAC4MEF2DEPHX2 | |
| SCHEMBL4404268 | 1.00 | CTSK (0.64) | CTSKGRIA1HDAC4MEF2DEPHX2 | |
| SCHEMBL7036665 | 0.86 | CTSK (0.53) | CTSKGRIA1HDAC4MEF2DHDAC1 | |
| SCHEMBL7036660 | 0.86 | CTSK (0.53) | CTSKGRIA1HDAC4MEF2DHDAC1 | |
| SCHEMBL8177757 | 0.86 | SMN1; SMN2 (0.60) | CTSKGRIA1HDAC4EPHX2HDAC1 | |
| SCHEMBL8861463 | 0.85 | EPHX2 (0.50) | CTSKGRIA1HDAC4EPHX2HDAC1 | |
| SCHEMBL8177140 | 0.85 | SMN1; SMN2 (0.59) | CTSKGRIA1HDAC4EPHX2HDAC1 | |
| SCHEMBL7036651 | 0.83 | SLC6A5 (0.52) | CTSKHDAC4MEF2DHDAC1SMN1; SMN2 | |
| SCHEMBL7034276 | 0.83 | P2RX7 (0.52) | CTSKMMP2MMP9FOLH1ERAP2 | |
| SCHEMBL7034270 | 0.83 | P2RX7 (0.52) | CTSKMMP2MMP9FOLH1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | claimed |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2013-07-04 | — | — | US | claimed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | claimed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | claimed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | claimed |
| US-11976382-B2 | Nucleic acid based biosensor and methods thereof | BOISE STATE UNIVERSITY (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| US-11807677-B2 | Microbe-binding molecules and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-07 | — | — | US | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220281955-A1 | MICROBE-BINDING MOLECULES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-09-08 | — | — | US | disclosed |
| US-11236149-B2 | Microbe-binding molecules and uses thereof | PRESIDENT AND FALLOWS OF HARVARD COLLEGE (US) | 2022-02-01 | — | — | US | disclosed |
| US-11021709-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-01 | — | — | US | disclosed |
| US-5470947-A | Lutenizing hormone-releasing hormone, contraceptives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0377665-B1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE | UNIV TEXAS (US) | 1995-07-12 | — | — | EP | disclosed |
| EP-0536203-B1 | COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS | APPLIED RESEARCH SYSTEMS (AN) | 1995-02-08 | — | — | EP | disclosed |
| WO-1991019743-A2 | COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1991-12-26 | — | — | WO | disclosed |
| EP-0377665-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE. | UNIV TEXAS (US) | 1990-07-18 | — | — | EP | disclosed |
| WO-1989009786-A1 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1989-10-19 | — | — | WO | disclosed |
| WO-1989001944-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | CTSK 2830/4885GRIA1 2019/4885HDAC4 677/4885 |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | CTSK 2725/4885GRIA1 535/4885HDAC4 2864/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | CTSK 1677/4885GRIA1 2260/4885HDAC4 1931/4885 |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | GHSR, GHRHR, GIPR | CTSK 3353/4885GRIA1 142/4885HDAC4 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.